Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Baricitinib in the Treatment of Refractory Axial Spondyloarthritis Patients: A Comparison With Tofacitinib

NCT06114407 is registered in ClinicalTrials.gov with Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh as lead sponsor.

NCT NCT06114407
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06114407 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Baricitinib in the Treatment of Refractory Axial Spondyloarthritis Patients: A Comparison With Tofacitinib
Lead sponsor
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Phase
Phase 2
Overall status
Unknown status
Start date
October 30, 2023
Completion date
December 30, 2024
Enrollment
184 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

spondyloarthritis, axial